Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ascendis Pharma ASMEX:ASNDN 37 EV-to-OCF is 190.70 as of Aug. 10, 2026, which is 15% below its 10-year median of 225.13. GuruFocus rates MEX:ASNDN with a GF Score™ of 37/100. The stock has 5 warning signs investors should review. Among 1,405 Biotechnology companies, Ascendis Pharma AS ranks worse than 98.93% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Ascendis Pharma AS's Enterprise Value is MXN242,855 Mil.
Ascendis Pharma AS's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was MXN1,273 Mil. Therefore, Ascendis Pharma AS's EV-to-OCF for today is 190.70.
The historical rank and industry rank for Ascendis Pharma AS's EV-to-OCF or its related term are showing as below:
MEX:ASNDN'
s EV-to-OCF Range Over the Past 10 Years
Min: 196.3 Med: 225.13 Max: 254.44
Current: 241.26
During the past 13 years, the highest EV-to-OCF of Ascendis Pharma AS was 254.44. The lowest was 196.30. And the median was 225.13.
MEX:ASNDN's EV-to-OCF is ranked worse than 98.93% of 1405
companies
in the Biotechnology industry
Industry Median: -3.45
vs MEX:ASNDN: 241.26
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ascendis Pharma AS (MEX:ASNDN) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ascendis Pharma AS's PE Ratio (TTM) for today is calculated as:
Ascendis Pharma AS's share price for today is MXN3851.44.
Ascendis Pharma AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-51.316.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Ascendis Pharma AS EV-to-OCF Related Terms
Ascendis Pharma AS EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Ascendis Pharma AS's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:ASNDN vs BBIO, JAZZ, EXEL: EV-to-OCF Comparison
For the Biotechnology subindustry, Ascendis Pharma AS's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascendis Pharma AS EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascendis Pharma AS's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Ascendis Pharma AS's EV-to-OCF falls into.
Ascendis Pharma AS's current Enterprise Value is MXN242,855 Mil.
Ascendis Pharma AS's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN1,273 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascendis Pharma AS (MEX:ASNDN) has a EV-to-OCF of 190.70 as of Aug. 10, 2026. This is 15% below median its historical median of 225.13. Over the past decade, Ascendis Pharma AS's EV-to-OCF has ranged from 196.30 to 254.44. According to the industry distribution chart, Ascendis Pharma AS ranks #1390 out of 1405 companies in the Biotechnology industry, placing it in the top 98.9%.
Is Ascendis Pharma AS's EV-to-OCF too high?
Ascendis Pharma AS's current EV-to-OCF of 190.70 is 15% below median its 10-year median of 225.13. Over the past 10 years, this metric has ranged from a low of 196.30 to a high of 254.44. Based on the distribution chart, Ascendis Pharma AS ranks #1390 out of 1405 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ascendis Pharma AS has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Ascendis Pharma AS's EV-to-OCF compare to BBIO and JAZZ?
According to the Biotechnology industry distribution chart, Ascendis Pharma AS ranks #1390 out of 1405 companies for EV-to-OCF. This places Ascendis Pharma AS in the lower half of its industry. Historically, Ascendis Pharma AS's own EV-to-OCF has ranged from 196.30 to 254.44 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Ascendis Pharma AS's current EV-to-OCF is 190.70, which is 15% below median its own 10-year median of 225.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascendis Pharma AS stock overvalued right now?
Ascendis Pharma AS (MEX:ASNDN) has a current EV-to-OCF of 190.70. The current EV-to-OCF is 190.70, which is 15% below median its 10-year median of 225.13. Ascendis Pharma AS's overall GF Score™ is 37/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Ascendis Pharma AS (MEX:ASNDN), the current EV-to-OCF is 190.70 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
37GF Score
Get the complete analysis for MEX:ASNDN
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ASNDN has been successfully added to your 
